Opus Genetics (IRD) Research & Development (2010 - 2026)
Opus Genetics (IRD) posted quarterly Research & Development of $10.6 million for Q1 2026, up 32.99% year-over-year from $8.0 million in Q1 2025, and up 1.43% quarter-over-quarter from $10.4 million in Q4 2025.
Opus Genetics (IRD) Research & Development (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Research & Development for 17 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 32.99% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $33.4 million (up 11.25% YoY), while the FY2025 annual figure was $30.8 million, up 14.75% from the prior year.
- Research & Development climbed to $10.6 million in Q1 2026 per IRD's latest filing, from $10.4 million in the prior quarter.
- Across five years, Research & Development topped out at $10.6 million in Q1 2026 and bottomed at $2.8 million in Q3 2022.
- Historically, Research & Development has averaged $5.9 million across 5 years, with a median of $5.6 million in 2023.
- Annual changes were most pronounced in 2024 — Research & Development soared 157.07% — and 2025, when it decreased 28.65%.
- Opus Genetics' Research & Development stood at $3.6 million in 2022, then increased by 7.11% to $3.8 million in 2023, then soared by 83.13% to $7.0 million in 2024, then surged by 48.25% to $10.4 million in 2025, then rose by 1.43% to $10.6 million in 2026.
- Business Quant data shows IRD's Research & Development at $10.6 million in Q1 2026, $10.4 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 11.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.21 Mn |
| Mar 31, 2026 | 10.58 Mn |
| Dec 31, 2025 | 10.43 Mn |
| Sep 30, 2025 | 6.41 Mn |
| Jun 30, 2025 | 6.02 Mn |
| Mar 31, 2025 | 7.95 Mn |
| Dec 31, 2024 | 7.03 Mn |
| Sep 30, 2024 | 8.98 Mn |
| Jun 30, 2024 | 6.09 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Dec 31, 2023 | 3.84 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 4.72 Mn |
| Mar 31, 2023 | 5.60 Mn |
| Dec 31, 2022 | 3.59 Mn |
| Sep 30, 2022 | 2.84 Mn |
| Jun 30, 2022 | 3.16 Mn |
| Mar 31, 2022 | 4.77 Mn |
| Dec 31, 2021 | 4.74 Mn |
| Sep 30, 2021 | 3.13 Mn |